Domov › Trojnásobne negatívny karcinóm prsníka › Georgia › Atlanta
Klinické štúdie Trojnásobne negatívny karcinóm prsníka v meste Atlanta, GA
20 štúdií pre Trojnásobne negatívny karcinóm prsníka hľadá účastníkov v zariadeniach v meste Atlanta a okolí (do cca 30 míľ). Otvorte štúdiu a zistite, kto sa môže zapojiť a ako kontaktovať tím.
Oficiálny text štúdie (anglicky)
Hľadáte účastníkov do štúdie? Zvýraznite ju na začiatku tejto stránky – $99 na 30 dní →
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Prebieha náborFáza 1
- Winship Cancer Institute of Emory University, Atlanta
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Prebieha náborFáza 1
- Emory University, Atlanta
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Prebieha náborFáza 1
- Emory Winship Cancer Institute, Atlanta
A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer
Prebieha náborFáza 2
- Emory University (Data Collection Only), Atlanta
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Prebieha náborFáza 3
- Piedmont Cancer Institute, Atlanta
- Northside Hospital, Atlanta
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Prebieha náborFáza 1
- Emory University, Atlanta
Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
Prebieha náborFáza 2
- Emory University, Atlanta
ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
Prebieha náborFáza 1/2
- Emory University Winship Cancer Institute, Atlanta
- Winship Cancer Institute of Emory University, Atlanta
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Prebieha náborFáza 2/3
- Northside Hospital, Atlanta
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Prebieha náborFáza 1/2
- Winship Cancer Institute, Emory University, Atlanta
Study of XB010 in Subjects With Solid Tumors
Prebieha náborFáza 1
- Winship Cancer Institute, Atlanta
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
Prebieha náborFáza 1
- Winship Cancer Institute / Emory University, Atlanta
Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer
Prebieha náborFáza 2
- Emory University Hospital, Atlanta
Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab
Prebieha náborObservačná štúdiaVítaní zdravých dobrovoľníkov
- Emory University/Winship Cancer Institute, Atlanta
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Prebieha náborFáza 2
- Winship Cancer Institute of Emory University, Atlanta
High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer
Prebieha náborFáza 2
- Emory University Hospital/Winship Cancer Institute, Atlanta
Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer
Prebieha náborFáza 1
- Emory University, Winship Cancer Institute, Atlanta
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
Prebieha náborFáza 1/2
- Winship Cancer Institute - Emory University, Atlanta
Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer
Prebieha náborFáza 1
- Grady Health System, Atlanta
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
- a 1 ďalších
A Beta-only IL-2 ImmunoTherapY Study
Prebieha náborFáza 1/2
- Emory - Winship Cancer Institute, Atlanta
Štúdie Trojnásobne negatívny karcinóm prsníka v iných mestách
- Houston, TX42 štúdií
- New York City, NY31 štúdií
- Nashville, TN28 štúdií
- Los Angeles, CA27 štúdií
- Boston, MA26 štúdií
- San Antonio, TX23 štúdií
- St. Louis, MO21 štúdií
- Arlington, VA20 štúdií
- Dallas, TX18 štúdií
- Chicago, IL16 štúdií
- Columbus, OH16 štúdií
- Grand Rapids, MI15 štúdií
Iné štúdie v Atlanta
- Rakovina (všetky typy)49 štúdií
- Nemalobunkový karcinóm pľúc47 štúdií
- Mnohonásobný myelóm42 štúdií
- Rakovina prsníka41 štúdií
- Rakovina prostaty33 štúdií
- Akútna myeloidná leukémia31 štúdií
- Rakovina vaječníkov29 štúdií
- Kolorektálny karcinóm29 štúdií
- Rakovina pľúc29 štúdií
- Metastatická rakovina28 štúdií
- Ťažká depresívna porucha25 štúdií
- Srdcové zlyhanie25 štúdií
Z ClinicalTrials.gov, dáta načítané 6. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.